Updates in Heart Failure 2023

Chairs: Gianluigi Savarese, Frieder Braunschweig

Organized by: Karolinska University Hospital
In collaboration with Translational Medical Academy Foundation (TMA)

December 11th-12th 2023

DECEMBER 11th 2023 (DAY 1)

Download Program

12.00-13.00

Lunch

12.00-13.00

  • 13.00-13.05 | Greetings and introduction to the congress
    Savarese G (SE), Braunschweig F (SE)
Session 1: Updates from the Heart Failure Association of the European Society of Cardiology

Chairpersons: Savarese G (SE), Rosano G (UK), Ponikowski P (PL)

13.20-14.35

  • 13.20-13.35 | Updates in European Guidelines on Heart failure: what changes and why?
    Metra M (IT)
  • 13.35-13.50 | Patient profiling in HFpEF: a roadmap to the treatment of patients with HFpEF
    Anker S (DE)
  • 13.50-14.05 | Latest HFA/ESC scientific statements
    Chioncel O (RO)
  • 14.05-14.35 | Round Table: Ask the experts
    All

14.35-14-50

Coffee Break
Session 2: Latest updates on SGLT2i – multidisciplinary perspectives

Chairpersons: Braunschweig F (SE), Solomon S (US), Lainscak M (SLO)

14.50-16.20

  • 14.50-15.00 | New data on empagliflozin in HF
    Anker S (DE)
  • 15.00-15.10 | New data on dapagliflozin in HF
    McMurray J (UK)
  • 15.10-15.20 | SGLT2i in kidney disease
    Lambers Heerspink H (NL)
  • 15.20-15.30 | SGLT2i in type 2 diabetes
    Cosentino F (SE)
  • 15.30-15.40 | What about the mechanisms?
    Ferrannini E (IT)
  • 15.40-15.50 – What to consider when starting a SGLT2i in a patient with cardiometabolic disease
    Rosano G (UK)
  • 15.50-16.20 | Round Table: Ask the experts
    All

16.20-16.35

Coffee Break
Session 3: Iron deficiency in HF: summing up the current evidence

Chairpersons: Maurizio Volterrani (IT), Butler J (US), Ponikowski P (PL)

16.35-17.40

  • 16.35-16.45 | Why to screen HF patients for iron deficiency? Epidemiology and Pathophysiology
    Von Haehling (DE)
  • 16.45-16.55 | Latest data on ferric carboxymaltose
    Ponikowki (PL)
  • 16.55-17.05 | Latest data on ferric derisomaltose
    Cleland J (UK)
  • 17.05-17.35 | Round Table: Ask the experts
    All
        • 17.35-17.55 | Keynote lecture: State-of-the-art on GLP1-Ra in heart failure
          Petrie M (UK)
        • 17.55-18.00 | Closure of the day
          Savarese G (SE), Braunschweig F (SE)

        December 12th 2023 (day 2)

        DECEMBER 12th 2023 (DAY 2)
        • 08.25-08.30 | Welcome and introduction
          Savarese G (SE), Braunschweig F (SE)
        Session 4: The evolving evidence on potassium binders

        08.30-09.30

        Chairpersons: Lund LH (SE), Ponikowki (PL)

        • 08.30-08.40 | Why do we need potassium binders?
          Savarese G (SE)
        • 08.40-08.50 | Latest data on patiromer
          Butler J (US)
        • 08.50-09:00 | Latest data on SZC
          Rosano G
        • 09.00-09.30 | Round Table: Ask the experts
          All
        Session 5: Beyond the 4 pillars of pharmacological treatment in HFrEF

        09.30-10.40

        Chairpersons: Metra M (IT), Swedberg K (SE)

        • 09.30-09.40 | Ivabradine
          Rosano G (UK)
        • 09.40-09.50 | Vericiguat
          Lund LH (SE)
        • 09.50-10.00 | Omecamtiv mecarbil
          Solomon S (US)
        • 10.00-10.10 | What is coming next?
          Filippatos G (GR)
        • 10.10-10.40 | Round Table: Ask the experts
          All

        10.40-10.55

        Coffee Break
        Session 6: Implementation of GDMT: where do we stand?

        10.55-11.55

        Chairpersons: Volterrani M (IT), Bayes-Genis A (ES), Cannata A (UK)

        • 10.55-11.05 | Status of GDMT implementation worldwide
          Savarese G (SE)
        • 11.05-11.15 | Strategies to implement use of GDMT in HF
          Bozkurt B (US)
        • 11.15-11.25 | Take home messages from the STRONG-HF trial
          Chioncel O (RO)
        • 11.25-11.55 | Round Table: Ask the experts
          All

        11.55-12.55

        Lunch
        Session 7: The complicated relationship between ischemic heart disease and heart failure

        12.55-14.05

        Chairpersons: Lund LH (SE), Lindmark K (SE)

        • 12.55-13.05 | The PARADISE-MI trial
          Solomon S (US)
        • 13.05-13.15 | The DAPA-MI
          James S (SE)
        • 13.15-13.25 | The EMPACT-MI
          Butler J (US)
        • 13.25-13.35 | The REVIVED
          Petrie M (UK)
        • 13.35-14.05 | Round Table: Ask the experts
          All
        Session 8: Heart Failure Devices

        14.05-14.55

        Chairpersons: Cleland J (UK), Linde C (SE)

        • 14.05-14.15 | Primary prophylactic ICD in HF: current debates
          Braunschweig F (SE)
        • 14.15-14.25 | Resynchronization by CRT or conduction system pacing
          Burri H (CH)
        • 14.25-14.35 | MONITOR HF
          Brugts J (NL)
        • 14.35-14.55 | Round Table: Still room for devices on top of pharmacological therapies?
          All

        14.55-15.10

        Coffee Break
        Session 9: Treating mitral and tricuspid regurgitation in HF

        15.10-16.00

        Chairpersons: Savarese G (SE), Braunschweig F (SE)

        • 15.10-15.20 | The importance to treat MR and TR in heart failure
          Butler J (US)
        • 15.20-15.35 | Treating MR in the context of HF effectively
          Adamo M (IT)
        • 15.35-15.50 | Treating TR today and tomorrow
          Lurz P (DE)
        • 15.50-16.00 | Round Table: Ask the experts
          All
        Session 10: The best of HF publications in 2023

        16.00-16.40

        Chairpersons: Savarese G (SE), Bayes-Genis A (ES)

        • 16.00-16.10 | European Journal of Heart Failure
          Metra M (IT)
        • 16.10-16.20 | JACC HF
          Bozkurt B (US)
        • 16.20-16.30 | ESC HF
          Bäck M (SE)
        • 16.30-16.40 | Key learnings and conclusion
          Savarese G (SE, Braunschweig F (SE)
        Scroll to Top